Vaxcyte officer plans $80K Rule 144 stock sale

An officer of Vaxcyte, Inc. filed a Form 144 to sell 1,334 common shares after several recent stock sales.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) is the issuer for which officer James Wassil has filed a notice under Rule 144 to sell common stock. The notice covers a proposed sale of 1,334 shares of common stock, with an indicated aggregate value of $80,026.66, following an RSU vest on September 7, 2026.

The filing also lists recent sales of Vaxcyte common stock for Wassil during the prior three months, including separate transactions of 2,250 shares on July 1, 2026, 2,250 shares on August 3, 2026, 3,477 shares on September 1, 2026, and 1,381 shares on September 4, 2026, all executed through a broker.

Key Figures

Proposed shares to be sold: 1,334 shares Proposed aggregate value: $80,026.66 Sale on July 1, 2026: 2,250 shares for $126,735.98 +4 more

7 metrics

Proposed shares to be sold 1,334 shares Common stock under Rule 144 notice

Proposed aggregate value $80,026.66 Indicated value for 1,334 shares in the Form 144

Sale on July 1, 2026 2,250 shares for $126,735.98 Common stock sold by James Wassil

Sale on August 3, 2026 2,250 shares for $121,194.45 Common stock sold by James Wassil

Sale on September 1, 2026 3,477 shares for $212,352.66 Common stock sold by James Wassil

Sale on September 4, 2026 1,381 shares for $84,462.51 Common stock sold by James Wassil

Form 144 notice date September 9, 2026 Date of the Rule 144 filing

Key Terms

Rule 144, RSU Vest, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vest financial

"Common | 09/07/2026 | RSU Vest | Issuer"

attorney-in-fact regulatory

"Signature | /s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the new Form 144 filing mean for Vaxcyte (PCVX)?

The filing reports that officer James Wassil plans to sell 1,334 shares of Vaxcyte common stock under Rule 144. It also discloses several sales of Vaxcyte shares in the prior three months, providing transparency about his recent trading activity.

How many Vaxcyte (PCVX) shares are proposed to be sold in this Form 144?

The notice covers a proposed sale of 1,334 shares of Vaxcyte common stock. The filing lists an indicated aggregate value of about $80,026.66 for these shares, based on the information provided for the planned transaction.

What Vaxcyte (PCVX) stock sales by James Wassil occurred in the past three months?

The filing lists four sales of Vaxcyte common stock by James Wassil: 2,250 shares on July 1, 2026, 2,250 shares on August 3, 2026, 3,477 shares on September 1, 2026, and 1,381 shares on September 4, 2026, each with reported dollar proceeds.

What dollar amounts were reported for recent Vaxcyte (PCVX) share sales?

Reported proceeds were $126,735.98 for 2,250 shares on July 1, 2026, $121,194.45 for 2,250 shares on August 3, 2026, $212,352.66 for 3,477 shares on September 1, 2026, and $84,462.51 for 1,381 shares on September 4, 2026.

What is the source of the shares in the new Form 144 for Vaxcyte (PCVX)?

The Form 144 states that the 1,334 shares proposed for sale relate to an RSU vest on September 7, 2026, with Vaxcyte, Inc. shown as the issuer of the vested restricted stock units.

Which broker is involved in the planned Vaxcyte (PCVX) share sale?

The proposed sale of 1,334 Vaxcyte common shares is listed through UBS Financial Services Inc., which is also identified as signing the notice as attorney-in-fact for James Wassil.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:13 PM Accepted by SEC EDGAR 09/09/2026 - 04:12 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	1334	80026.66	148805278	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/07/2026	RSU Vest	Issuer			1334	09/07/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	07/01/2026	2250	126735.98
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	08/03/2026	2250	121194.45
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	09/01/2026	3477	212352.66
James Wassil 825 INDUSTRIAL ROAD STE 300 San Carlos CA 94070	Common	09/04/2026	1381	84462.51

144: Remarks and Signature

Remarks
Date of Notice	09/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)